Aerie Pharmaceuticals reported $312.13M in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
Alimera Sciences ALIM:US $ 43.8M 0.2M
Amarin AMRN:US $ 0M 0M
Bluebird Bio BLUE:US $ 0M 0M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 196.04M 224.42M
Endo International Ordinary Shares ENDP:US $ 8065.3M 25.32M
Horizon Pharma HZNP:US $ 2566.99M 1.75M
Insmed INSM:US $ 807.32M 534K
JAZZ PHA JAZZ:US $ 6021M 2.87M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 31031M 244M
Ophthotech OPHT:US $ 0M 0M
Pacira Pharmaceuticals PCRX:US $ 755.65M 167.77M
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Revance Therapeutics RVNC:US $ 396.1M 53.64M
Supernus Pharmaceuticals SUPN:US $ 400.91M 0.53M
Teva Pharmaceutical Industries TEVA:US $ 22082M 835M
Valeant Pharmaceuticals VRX:CN $ 28078.98M 4910.98M
Zoetis ZTS:US $ 6573M 5M